EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets

Abaher O ALTamimi, Noha M Elemam, Shirin Hafezi, Maha Saber-Ayad, Iman M Talaat

Frontiers in Pharmacology · 30.04.2026 · 17

DOI: 10.3389/fphar.2026.1807304 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.04.2026. Verfasst von Abaher O ALTamimi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 153 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Sharjah.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) is marked by an intricate interaction of genetic mutations with the tumor microenvironment (TME). This review will provide updated insights into the effects of major mutations in CRC patients, including MMR , APC, KRAS, BRAF, PIK3CA, and TP53, on tumor progression and highlight their dynamic interactions with the TME, which can modulate, mask, or convert therapeutic sensitivity or resistance. Mutations in the KRAS and BRAF genes, for instance, have been associated with adverse outcomes and therapy resistance in CRC patients. Tumor profiling is significant for predicting prognosis and treatment responses, since mutation-specific crosstalk with the TME clarifies opportunities for personalized treatment strategies. Moreover, combination therapies targeting the multifaceted pathways of tumor cells and TME components have the potential to overcome drug resistance. New approaches in therapy are highly promising, especially in targeting the Wnt/β-catenin pathway, restoring APC function, and exploiting synthetic lethal interactions with truncated APC using next-generation small-molecule inhibitors, such as TASIN-1. More research is necessary to fully elucidate the interconnections among specific mutations, the TME, and treatment responsiveness to develop personalized therapies.

Schlagwörter

Stichwörter der Autor:innen

colorectal cancerdrug resistancegenetic alterationsmicrosatellite instability (MSI)mismatch repair (MMR)tumor microenvironment (TME)

Autor:innen und Institutionen

  • Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates.
  • Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
  • College of Medicine, Cairo University, Giza, Egypt.
  • Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Förderung

  • University of Sharjah

Zitieren

APA

ALTamimi, A. O., Elemam, N. M., Hafezi, S., Saber-Ayad, M., & Talaat, I. M. (2026). Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1807304

Vancouver

ALTamimi AO, Elemam NM, Hafezi S, Saber-Ayad M, Talaat IM. Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1807304

BibTeX
@article{ALTamimi2026,
  author = {ALTamimi, Abaher O and Elemam, Noha M and Hafezi, Shirin and Saber-Ayad, Maha and Talaat, Iman M},
  title = {Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1807304}
}
Kostenlos starten →